Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial
- PMID: 39603693
- DOI: 10.1136/bmj.q2623
Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial
Erratum for
-
Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.BMJ. 2024 Nov 18;387:e079525. doi: 10.1136/bmj-2024-079525. BMJ. 2024. PMID: 39557487 Free PMC article. Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources